ERBB2 and triple-negative breast carcinoma: A germline mutation in EIF2AK4 (rs35602605) was present in 46% of the triple negative breast cancer (TNBC) cases compared to 27% of the ER-positive/HER2-negative (ER+) cases (P = 0.009), confirming the results from our cohort (Table 2).